The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19 : A prospective real-world cohort study
BACKGROUND: Protective effects of Bacillus Calmette-Guérin (BCG) vaccination and clofazimine and dapsone treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. Patients at risk for leprosy represent an interesting model for assessing the effects of these therapies on the occurrence and severity of coronavirus disease 2019 (COVID-19). We assessed the influence of leprosy-related variables in the occurrence and severity of COVID-19.
METHODOLOGY/PRINCIPAL FINDINGS: We performed a 14-month prospective real-world cohort study in which the main risk factor was 2 previous vaccinations with BCG and the main outcome was COVID-19 detection by reverse transcription polymerase chain reaction (RT-PCR). A Cox proportional hazards model was used. Among the 406 included patients, 113 were diagnosed with leprosy. During follow-up, 69 (16.99%) patients contracted COVID-19. Survival analysis showed that leprosy was associated with COVID-19 (p<0.001), but multivariate analysis showed that only COVID-19-positive household contacts (hazard ratio (HR) = 8.04; 95% CI = 4.93-13.11) and diabetes mellitus (HR = 2.06; 95% CI = 1.04-4.06) were significant risk factors for COVID-19.
CONCLUSIONS/SIGNIFICANCE: Leprosy patients are vulnerable to COVID-19 because they have more frequent contact with SARS-CoV-2-infected patients, possibly due to social and economic limitations. Our model showed that the use of corticosteroids, thalidomide, pentoxifylline, clofazimine, or dapsone or BCG vaccination did not affect the occurrence or severity of COVID-19.
| Errataetall: |
CommentIn: Indian J Dermatol Venereol Leprol. 2023 Jan-Frebuary;89(1):133-134. - PMID 36331835 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
PLoS neglected tropical diseases - 15(2021), 7 vom: 28. Juli, Seite e0009635 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cerqueira, Selma Regina Penha Silva [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z8R6ORS6L |
|---|
| Anmerkungen: |
Date Completed 17.08.2021 Date Revised 02.11.2023 published: Electronic-eCollection CommentIn: Indian J Dermatol Venereol Leprol. 2023 Jan-Frebuary;89(1):133-134. - PMID 36331835 Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.pntd.0009635 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328646458 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328646458 | ||
| 003 | DE-627 | ||
| 005 | 20231225203358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pntd.0009635 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328646458 | ||
| 035 | |a (NLM)34319982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cerqueira, Selma Regina Penha Silva |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19 |b A prospective real-world cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2021 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a CommentIn: Indian J Dermatol Venereol Leprol. 2023 Jan-Frebuary;89(1):133-134. - PMID 36331835 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Protective effects of Bacillus Calmette-Guérin (BCG) vaccination and clofazimine and dapsone treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. Patients at risk for leprosy represent an interesting model for assessing the effects of these therapies on the occurrence and severity of coronavirus disease 2019 (COVID-19). We assessed the influence of leprosy-related variables in the occurrence and severity of COVID-19 | ||
| 520 | |a METHODOLOGY/PRINCIPAL FINDINGS: We performed a 14-month prospective real-world cohort study in which the main risk factor was 2 previous vaccinations with BCG and the main outcome was COVID-19 detection by reverse transcription polymerase chain reaction (RT-PCR). A Cox proportional hazards model was used. Among the 406 included patients, 113 were diagnosed with leprosy. During follow-up, 69 (16.99%) patients contracted COVID-19. Survival analysis showed that leprosy was associated with COVID-19 (p<0.001), but multivariate analysis showed that only COVID-19-positive household contacts (hazard ratio (HR) = 8.04; 95% CI = 4.93-13.11) and diabetes mellitus (HR = 2.06; 95% CI = 1.04-4.06) were significant risk factors for COVID-19 | ||
| 520 | |a CONCLUSIONS/SIGNIFICANCE: Leprosy patients are vulnerable to COVID-19 because they have more frequent contact with SARS-CoV-2-infected patients, possibly due to social and economic limitations. Our model showed that the use of corticosteroids, thalidomide, pentoxifylline, clofazimine, or dapsone or BCG vaccination did not affect the occurrence or severity of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Dapsone |2 NLM | |
| 650 | 7 | |a 8W5C518302 |2 NLM | |
| 650 | 7 | |a Clofazimine |2 NLM | |
| 650 | 7 | |a D959AE5USF |2 NLM | |
| 650 | 7 | |a Pentoxifylline |2 NLM | |
| 650 | 7 | |a SD6QCT3TSU |2 NLM | |
| 700 | 1 | |a Deps, Patrícia Duarte |e verfasserin |4 aut | |
| 700 | 1 | |a Cunha, Débora Vilela |e verfasserin |4 aut | |
| 700 | 1 | |a Bezerra, Natanael Victor Furtunato |e verfasserin |4 aut | |
| 700 | 1 | |a Barroso, Daniel Holanda |e verfasserin |4 aut | |
| 700 | 1 | |a Pinheiro, Ana Bárbara Sapienza |e verfasserin |4 aut | |
| 700 | 1 | |a Pillegi, Gecilmara Salviato |e verfasserin |4 aut | |
| 700 | 1 | |a Repsold, Taynah Alves Rocha |e verfasserin |4 aut | |
| 700 | 1 | |a Kurizky, Patrícia Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Collin, Simon M |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Ciro Martins |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLoS neglected tropical diseases |d 2007 |g 15(2021), 7 vom: 28. Juli, Seite e0009635 |w (DE-627)NLM17489287X |x 1935-2735 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:7 |g day:28 |g month:07 |g pages:e0009635 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pntd.0009635 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 7 |b 28 |c 07 |h e0009635 | ||